Cat. No.: HY-101566

Elimusertib

(Synonyms: BAY 1895344)

17 Cited Publications

Customer Review

Based on 17 publication(s) in Google Scholar

Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity. Elimusertib can be used for the research of solid tumors and lymphomas.

For research use only. We do not sell to patients.

Purity: 99.73%
CAS No.: 1876467-74-1
Formula: C₂₀H₂₁N₇O
Molecular Weight:375.43

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Elimusertib Chemical Structure

CAS No.: 1876467-74-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (17)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity^[1]^[2]. Elimusertib can be used for the research of solid tumors and lymphomas^[3].

IC₅₀ & Target^[1]

ATR

7 nM (IC₅₀)

All ATM/ATR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.09 μM Compound: BAY1895344	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 35191694]
HEK293	IC₅₀	>10 μM Compound: BAY-1895344	Inhibition of recombinant human ERG stably expressed in HEK293 cells at -80 mV by whole cell voltage clamp method Inhibition of recombinant human ERG stably expressed in HEK293 cells at -80 mV by whole cell voltage clamp method	[PMID: 32502336]
HT-29	IC₅₀	160 nM Compound: BAY-1895344	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay	[PMID: 32502336]
HT-29	IC₅₀	36 nM Compound: BAY-1895344	Inhibition of ATR in human HT-29 cells assessed as reduction in histone H2AX phosphorylation measured after 30 mins by immunofluorescence cytometric assay Inhibition of ATR in human HT-29 cells assessed as reduction in histone H2AX phosphorylation measured after 30 mins by immunofluorescence cytometric assay	[PMID: 32502336]
LoVo	IC₅₀	0.041 μM Compound: 5; BAY1895334	Antiproliferative activity against human LoVo cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells incubated for 72 hrs by CCK-8 assay	[PMID: 37130473]
LoVo	IC₅₀	27 nM Compound: 4	Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo assay Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo assay	[PMID: 38299539]
LoVo	IC₅₀	71 nM Compound: BAY-1895344	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay	[PMID: 32502336]
MCF7	IC₅₀	35 nM Compound: BAY-1895344	Inhibition of PI3K/AKT/mTOR signaling pathway in human MCF7 cells assessed as reduction in AKT phosphorylation at Ser473 residues measured after 30 mins by HTRF assay Inhibition of PI3K/AKT/mTOR signaling pathway in human MCF7 cells assessed as reduction in AKT phosphorylation at Ser473 residues measured after 30 mins by HTRF assay	[PMID: 32502336]
SU-DHL-8	IC₅₀	9 nM Compound: 8	Antiproliferative activity against human SU-DHL-8 cells measured after 72 to 96 hrs by CellTiter-Glo cell viability assay Antiproliferative activity against human SU-DHL-8 cells measured after 72 to 96 hrs by CellTiter-Glo cell viability assay	[PMID: 33135887]
SU-DHL-8	IC₅₀	9 nM Compound: BAY-1895344	Antiproliferative activity against human SUDHL8 cells assessed as reduction in cell viability measured after 4 days by celltiter-glo luminescent assay Antiproliferative activity against human SUDHL8 cells assessed as reduction in cell viability measured after 4 days by celltiter-glo luminescent assay	[PMID: 32502336]

In Vitro

Elimusertib potently inhibits the proliferation of a broad spectrum of human tumor cell lines with a median IC₅₀ of 78 nM^[1].
Elimusertib potently suppresses hydroxyurea-induced H2AX phosphorylation (IC₅₀: 36 nM)^[1].
Elimusertib shows good selectivity against mTOR (ratio of IC₅₀ values: mTOR/ATR 61)^[3].
Elimusertib reveals high selectivity against other related kinases, such as DNA-PK (IC₅₀: 332 nM), ATM (IC₅₀: 1420 nM), and PI3K (IC₅₀: 3270 nM)^[3].
Elimusertib has potent antiproliferative activity against various cancer cell lines in vitro, 25 for example in the CRC cell lines HT-29 (IC₅₀: 160 nM) and LoVo (IC₅₀: 71 nM), and in the B-cell lymphoma cell line SU-DHL-8 (IC₅₀: 9 nM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Elimusertib shows potent anti-tumor efficacy in monotherapy in a variety of xenograft models of ovarian and colorectal cancer, and causes complete tumor remission in mantle cell lymphoma models^[2].
Elimusertib (50 mg/kg; p.o.; b.i.d.; 3 days on/4 days off; for 11 days) exhibits strong antitumor efficacy in the ATM-mutated SU-DHL-8 (ATM K1964E) human GCB-DLBCL cell line derived xenograft model in mice^[3].
Elimusertib (20 mg/kg, and 10 mg/kg from day 14; p.o.; daily; 2 days on/5 days off; for 42 days) in combination with Carboplatin (40 mg/kg; i.p.; daily; 1 day on/6 days off) results in synergistic antitumor activity in the platinum-resistant ATM protein low expressing CR5038 human CRC PDX model in NOD/SCID mice^[3].
Elimusertib exhibits moderate oral bioavailability (rat 87%, dog 51%) following oral administration (rat and dog 0.6-1 mg/kg)^[3].
Elimusertib exhibits terminal elimination half-lives (mouse 0.17 h, rat 1.3 and, dog 1.0 h) due to plasma clearance (3.5, 1.2, and 0.79 L/h/kg respectively) following intravenous administration (mouse, rat and dog 0.3-0.5 mg/kg)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C.B-17 SCID mice, SU-DHL-8 GCB-DLBCL xenograft model^[3]
Dosage:

50 mg/kg
Administration:

Oral administration, b.i.d., 3 days on/4 days off, for 11 days
Result:

Inhibited tumor area.

Animal Model:

Male Wistar rats^[3]
Dosage:

0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis)
Administration:

Intravenous injection and oral administration
Result:

Oral bioavailability (87%), T_1/2 (1.3 h).

Animal Model:

Female beagle dogs^[3]
Dosage:

0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis)
Administration:

Intravenous injection and oral administration
Result:

Oral bioavailability (51%), T_1/2 (1.0 h).

Chemical Information

CAS No. 1876467-74-1
Appearance Solid
Molecular Weight 375.43
Formula C₂₀H₂₁N₇O
Color Light yellow to yellow
SMILES

CN1N=CC=C1C2=C(C=CN=C3C4=CC=NN4)C3=NC(N5[C@H](C)COCC5)=C2
Synonyms

BAY 1895344
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (17)

All WBBio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cancer Res

Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells. [Abstract]

2022 Mar 15;82(6):1013-1024. PMID: 35022212
Nat Commun

X-ray preactivated reversible persistent luminescence enables photodynamic immunotherapy of deep tumors. [Abstract]

2026 Mar 21. PMID: 41865031
Nat Commun

Stepwise phosphorylation and SUMOylation of PIDD1 drive PIDDosome assembly in response to DNA repair failure. [Abstract]

2024 Oct 24;15(1):9195. PMID: 39448602

Elimusertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 24;15(1):9195. [Abstract]

PIDD1−/− HeLa cells transfected with indicated FLAG-PIDD1 variants with or without ATR inhibitor BAY 1895344 (BAY, 0.75 mM)were harvested at 24 h, immunoprecipitated with anti-PIDD1 pT788 antibody, and analyzed by western blot.
Exp Mol Med

Inhibition of GSK3β is synthetic lethal with FHIT loss in lung cancer by blocking homologous recombination repair. [Abstract]

2025 Feb;57(1):167-183. PMID: 39762409

Elimusertib purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Feb;57(1):167-183. [Abstract]

Effects of Elimusertib on p-BRCA1 (s1423), BRCA1, and RAD51 protein levels. The cells were treated with 0.2 μM Elimusertib for 24 h, and Western blotting was used to detect protein expression. GAPDH was used as the internal control. All FHIT-deficient cells are marked in red.
Sci Adv

PARP4 ADP-ribosylates PIDD1 to complete a phospho/SUMO/PAR-ylation cascade that orchestrates PIDDosome assembly. [Abstract]

2026 May;12(18):eadz9284. PMID: 42054439
Cell Rep Med

Organoid morphology-guided classification for oral cancer reveals prognosis. [Abstract]

2025 May 6:102129. PMID: 40359934

Elimusertib purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 May 6:102129. [Abstract]

Comparison of synergy scores for cisplatin by target drug. The Bliss score was calculated using SynergyFinder to evaluate the synergistic effects of BAY1895344 (0.01 μM; 5 days), AZD7762, EPZ015666, or everolimus in combination with cisplatin across 27 OSCC organoids, comprising 10 normal-like, 8 dense, and 9 grape-like subtypes.
Cancer Lett

2026 Feb 4;642:218300.
Cancer Lett

Targeting ATR signaling in sarcoma with homologous recombination deficiency. [Abstract]

2026 Apr 1:642:218300. PMID: 41651400
J Med Chem

Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500). [Abstract]

2024 Feb 22;67(4):2349-2368. PMID: 38299539
EMBO Rep

Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors. [Abstract]

2024 Mar;25(3):1469-1489. PMID: 38366255

Elimusertib purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2024 Mar;25(3):1469-1489. [Abstract]

Cell viability assays in HCT116 and HT-29 cancer cells cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATRi Elimusertib (0.03-1 μM) for 72 h.
Biochem Pharmacol

Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells. [Abstract]

2023 May:211:115494. PMID: 36924905

Elimusertib purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 May:211:115494. [Abstract]

Elimusertib (10 μM; 1 h) pretreatment inhibits Ara-C-induced p38 MAPK phosphorylation but does not inhibit AKT dephosphorylation.
RSC Adv

Injectable thermosensitive hydrogel co-loading with ATRi and doxorubicin for the treatment of triple-negative breast cancer. [Abstract]

2025 Jun 16;15(26):20385-20396. PMID: 40530304
Mol Cell Biol

Kinase Inhibitor-Induced Cell-Type Specific Vacuole Formation in the Absence of Canonical ATG5-Dependent Autophagy Initiation Pathway. [Abstract]

2025;45(3):99-115. PMID: 39895059
bioRxiv

Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis. [Abstract]

2025 Sep 29:2025.09.28.674326. PMID: 41256360
Research Square Preprint

2023 Nov 20.
Research Square Preprint

2023 Jun 9.
Research Square Preprint

2023 May 17.

Solvent & Solubility

In Vitro:

DMSO : 5.4 mg/mL (14.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6636 mL

13.3181 mL

26.6361 mL

5 mM

0.5327 mL

2.6636 mL

5.3272 mL

10 mM

0.2664 mL

1.3318 mL

2.6636 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.09 mg/mL (2.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.09 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.9 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 0.89 mg/mL (2.37 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.89 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.9 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 4 mg/mL (10.65 mM); Suspended solution; Need ultrasonic and adjust pH to 3 with HCl

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement.

[2]. Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement

[3]. Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63(13):7293-7325. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6636 mL	13.3181 mL	26.6361 mL	66.5903 mL
	5 mM	0.5327 mL	2.6636 mL	5.3272 mL	13.3181 mL
	10 mM	0.2664 mL	1.3318 mL	2.6636 mL	6.6590 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Elimusertib

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Elimusertib

All ATM/ATR Isoforms

Biological Activity

Chemical Information

Publications (17)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Elimusertib

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Elimusertib

All ATM/ATR Isoforms

Biological Activity

Chemical Information

Publications (17)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Elimusertib Related Classifications

HY-101566 Related Classifications